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Novel therapeuticsLeukemia is a cancer of the white blood cells, with over 54,000 new cases per year diagnosed worldwide and a
5-year survival rate below 60%. This highlights a need for research into the mechanisms behind its etiology and
causes of therapy failure. The bone marrow microenvironment, in which adult stem cells are maintained in
healthy individuals, has been implicated as a source of chemoresistance and disease relapse. Here the various
ways that the microenvironment can contribute to the resistance and persistence of leukemia are discussed.
The targeting of the microenvironment by leukemia cells to create an environment more suitable for cancer pro-
gression is described. The role of soluble factors, drug transporters, microvesicles, as well as the importance of di-
rect cell–cell contact, in addition to the effects of inﬂammation and immune surveillance in microenvironment-
mediateddrug resistance are discussed. An overviewof the clinical potential of translating researchﬁndings to pa-
tients is also provided. Understanding of and further research into the role of the bonemarrowmicroenvironment
in leukemia progression and relapse are crucial towards developing more effective treatments and reduction in
patient morbidity. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer
Cell Survival, Metastasis, Inﬂammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L. Semenza.
Crown Copyright © 2015 Published by Elsevier B.V. All rights reserved.1. Introduction
Recent advances in understanding the role of the tumor microenvi-
ronment (TME) in cancer and the central role of the stromal cells have
uncovered new potential therapeutic opportunities to target cancer
development and progression. Of particular interest is the effect of the
microenvironment on hematological malignancies, usually referring to
several levels of crosstalk between leukemia cells and the bone marrow
microenvironment. This process is mediated in several different ways,
for example by soluble factors and cell–cell contact and is suggested to
affect chemotherapeutic response, potentially contributing to leukemia
relapse. Different pathways play a role in the interaction between leuke-
mia and the microenvironment depending on the type of leukemia. For
example B cell receptor (BCR) associated kinases are important for
chronic lymphocytic leukemia (CLL) expansion and maintenance.
Adhesion molecules, cytokines and other signaling molecules all play a
role in themovement and homing of leukemia, and have been identiﬁedicroenvironment Regulation of
ne Surveillance edited by Peter
fe Sciences, College of Science &
alford, Salford M5 4WT, United
. Krstic-Demonacos).
r B.V. All rights reserved.as potential targets for drug development, and are at different stages
of clinical trials [1]. In chronicmyeloid leukemia (CML) therapeutic resis-
tance can be induced by altered signaling between microenvironment
and leukemia cells that involves aberrant mRNA splicing of GSK3 beta
and BCL-2 family [2]. The microenvironment has also been shown to
be important for the acute myeloid leukemia (AML), with leukemic
cells interfering with the function of hematopoietic niche [3]. However,
the molecular details and clinical utility of these and other ﬁndings rele-
vant to understanding the role of the bonemarrowmicroenvironment in
leukemia progression and treatment are yet to be fully elucidated.
This review will describe how the crosstalk between the bone mar-
row niche and leukemia affects drug response. In particular the focus
will be on the role of soluble factors and cell–cell interactions in this
crosstalk. The relevance of inﬂammation and immune surveillance in
leukemia drug response and niche function will also be discussed. Last-
ly, a summary of clinical applications to date of manipulating microen-
vironment for leukemia therapy will be discussed.1.1. Hematopoiesis and the bone marrow microenvironment
Cells in the blood consist of a variety of types, each differentiated to
carry out a specialized function. For example there are erythrocytes (red
blood cells, involved in oxygen transport), platelets (involved in blood
clotting) and leukocytes (white blood cells, involved in the immune
415E. Bakker et al. / Biochimica et Biophysica Acta 1863 (2016) 414–426response). Each of these cell types share a common progenitor cell,
knownas a hematopoietic stem cell (HSC) [4]. The process of anHSCdif-
ferentiating into amore specialized cell is known as hematopoiesis. Due
to the fact that the body produces a large number of different blood cells
every day [5], the process of hematopoiesis and the maintenance of
HSCs are tightly regulated. HSCs are maintained in quiescent states
through specialized microenvironment known as niches. HSCs speciﬁ-
cally are known to be maintained within the bone marrow. In order
for cells to be affected by the bone marrow microenvironment they
must ﬁrst be localized to that area. Homing describes the phenomenon
of the migration of HSCs through the blood to different organs and to
the niches of the bone marrow [6]. It has been shown that expression
of signalingmolecules and integrins is crucial to the homing of leukemic
cells to the bone marrow and other locations [7].
The word microenvironment is used to describe certain parts of the
body where surrounding cells and tissues can affect the growth of
speciﬁc cells by altering the pH, oxygen levels and other factors. The
link between microenvironment and cancer was described by Stephen
Paget who developed the seed (tumor cells) and soil (microenviron-
ment) hypothesis, building on earlier idea by Ernst Fuchs, stating that
some tumor cells growpreferentially in certain organmicroenvironment
[8]. Microenvironment plays an important role in both health and dis-
ease. For example, the healthy body contains microenvironment which
supports the maintenance of stem cells, often referred to as stem cell
niches. However, when dysfunctional, these niches can ultimately play
an important role in disease progression, especially in cancer [9].
The bone marrow was classically described to have two niches:
the endosteal (osteoblastic) niche and the vascular (sinusoidal) niche
(Fig. 1) [9]. Early observations showed that primitive hematopoietic
cells tended to localize near the endosteal margins, thus promoting
the theory that bone played a role in the regulation of hematopoiesis.
This work was later expanded upon, where it was discovered that oste-
oblasts could support hematopoietic cells in culture [10]. The endostealFig. 1. The niches of the bone marrow. The bone marrow is classically described to contain two
involved in the maintenance of HSCs (red circles) and LSCs (yellow circles) that may alter the
in and out of the bone marrow and play a role in the vascular niche's role in supporting and m
and CXCL12.niche comprises the inner surface of the bone cavity and is lined by cells
such as osteoblasts and osteoclasts, involved in osteogenesis.
The vascular niche of the bonemarrow comprises a variety of struc-
tures. Sinusoids are small blood vessels with thin walls that serve as an
interface for communication between themarrowcavity and circulating
blood, allowing cells to trafﬁc in and out of the bone marrow [11]. The
interface between bone cells, HSCs and endothelial cells are crucial for
hematopoiesis and bone formation. The vascular niche plays three im-
portant roles in bone marrow: supplying oxygen, nutrients and growth
factors to HSCs to promote proliferation and differentiation; encourage-
ment of homing and mobilization through chemokines and sinusoidal
endotheliumand lastly the vascular niche is also important for cells out-
side of the bone marrow, such as in the spleen which may replace the
niche in case of bone marrow suppression [12].
Understanding the maintenance of stem cells in the absence of dis-
ease is crucial, as these niches and the cells themselves may be altered
through the course of illness. Evidence has shown that during cancer,
there exists a class of cells known as cancer stem cells (CSCs), a subtype
of a tumor that has stem-like properties, are capable of self-renewal but
have deregulated pathways [13]. Cancer stem cells have been identiﬁed
in a variety of cancers with leukemic stem cells (LSCs) being identiﬁed
in different types of leukemia [14]. For a comprehensive review of
CSCs, see Ajani et al. (2015) [13].
As described above, stem cells are maintained in speciﬁc niches that
allow them to remain in a quiescent state. During cancer, however,
these niches can be used by CSCs, and can also be affected by them to
create an environment more favorable to cancer [15]. It has been
shown in leukemia that LSCs can overtake the microenvironment with-
in the bonemarrow resulting in its altered function [14]. Therefore, suc-
cessful treatment of leukemia means not only treating the leukemia
cells which circulate through the blood, but also eliminating LSCs. The
paragraphs below discuss the role of the bone marrow niches in main-
tenance of HSCs and LSCs.niches, the osteoblastic (endosteal, left) and vascular (sinusoidal, right) niches. Both are
niche to their favor. Sinusoids (red dodecagon) in the vascular niche allow for trafﬁcking
obilizing HSCs. A variety of factors have been suggested to regulate HSCs, such as MMP9
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potentially through cell contact (via adhesion molecules) of HSCs with
osteoblasts. The osteoblastic niche was thus thought to contribute posi-
tively and negatively to HSC-state. Positive effects include osteoblasts
signaling through Jagged-1, reaching the corresponding receptor
NOTCH on the HSC cell, ultimately expanding the HSC pool. However,
osteoblasts also express osteopontin, which reduces HSC levels by the
inhibition of proliferation and promotion of apoptosis. Chemokine
(C-X-C motif) ligand 12 (CXCL12), a chemotactic molecule produced
by osteoblasts, was thought to be important for the recruitment of
HSCs to the bone marrow [16]. Recent evidence has suggested that the
endosteumcan secrete factors that helpmaintainHSCs into surrounding
niches [11] and exerts its effect on HSCs, as has been reviewed in-depth
[10,14]. It was also shown, through in vivo imaging, that fewHSCs are in
contact with osteoblasts [10]. Factors important in the maintenance of
HSCs by the endosteal niche include the proteases matrix metallo-
proteinase 9 (MMP9), cathepsin K and growth factors [11]. Other factors
include angiopoietin-1, stem cell factor (SCF), thrombopoietin and
CXCL12, all of which are involved in HSC maintenance [9,16].
It has also been shown that interruption of the signals that maintain
HSCs can improve chemotherapy. For example, TGF-β plays a role in the
quiescence of HSCs; however, blockage of TGF-β improved sensitivity to
chemotherapy [14]. LSCs have been implicated in drug resistance and
disease relapse and retaining minimal residual disease (small number
of leukemic cells that remain after chemotherapy) [17]. Understanding
the mechanisms behind drug resistance that allow LSCs to survive is
therefore crucial to improve therapy.
There are two classiﬁcations for chemoresistance in LSCs: intrinsic
factors (i.e., signaling pathways within the LSCs themselves) and ex-
trinsic factors (i.e., components generated by the bone marrow/other
microenvironment) [18]. One of the more important regulators of
chemoresistance is the cell cycle status of the cell; many chemothera-
peutic drugs target cycling cells. However, like HSCs, LSCs often reside
in a quiescent state, likely reducing the efﬁcacy of chemotherapy
drugs that target cycling cells [18]. Use of drugs that target LSCs regard-
less of cycling status is a feasible option, though it has also been shown
that inducing the cell cycle in LSCs, and following this with traditional
chemotherapy despite potential risks could be effective [19].
One of the main intrinsic pathways deregulated in LSCs is NF-κB
pathway that has been shown to be constitutively activated in LSCs, in-
dicating a role for it in survival; furthermore many of the drugs which
are shown to be effective against LSCs are known NF-κB inhibitors
[18]. Other pathways and mediators have been implicated in LSC/HSC
survival, such as Akt phosphatidylinositol-3 kinase (PI3K) [20], NOTCH
signaling [18], and the Wnt/β-catenin pathway [21]. It is possible to
target these pathways, such as the case of inhibiting the activation of
Akt by phosphatidylinositol 3 kinase (PI3K) inhibitors. Sinclair and col-
leagues [21] provide a detailed overview of the various survival path-
ways in CML stem cells, in addition to discussing methods to target
the pathways.
Extrinsic factors have been described as “environment-mediated
drug resistance” [18], arising from the protective effect of the microen-
vironment. Niche stromal cells affect malignant hematological cells by
preventing apoptosis through the positive regulation of anti-apoptotic
proteins. It has been reported that stromal cells protected co-cultured
leukemia cells from both drug-induced (cytarabine/ara-C) apoptosis
and apoptosis following serum starvation, correlatingwith the patient's
response to chemotherapy in vivo. Further to this, this protection was
shown to be through soluble factors as opposed to amechanism requir-
ing cell–cell contact. It was shown that BCL-2 was signiﬁcantly upregu-
lated in leukemia cells co-cultured with stromal cells, when compared
to cells that had not undergone co-culture, highlighting a way that
this protection could have occurred [22].
Drug resistance can develop in the continuous presence of chemo-
therapeutic drugs, leading to genetic and epigenetic changes in the
cells that confer resistance (Table 1) [23–51]. One of the main causesof drug resistance is altered function of efﬂux transporters that under
certain conditions in cancer transport drugs out of the cell. The follow-
ing section will discuss in more depth the role of drug transporters in
leukemia resistance.
1.2. Efﬂux pumps as a means of chemoresistance
One of the primary ways in which cancer and stem cells may employ
protection is through the expression of adenosine triphosphate-binding
cassette (ABC) efﬂux transporters, which are known to bemultifunction-
al [52]. Some cancer cells are resistant to chemotherapy and their contin-
ued proliferation may ultimately lead to development to multidrug
resistance (MDR) [53]. The aforementioned ABC transporters have
been implicated in MDR, as they are known to shield CSCs from the che-
motherapeutic effect by active excretion of a variety of chemotherapy
drugs. This links theABC transporters toMDR,which is an important pro-
cess to understand as it represents a major issue in chemotherapy treat-
ment [54]. MDR in general may arise not only through efﬂux by ABC
transporters, but also through phenomena such as reduction in drug up-
take and imbalances in cell growth, survival and death signaling [55].
There are over 40 different human ABC genes, and each of them has
been linked to disease when their function is defective and deregulated
[54,56]. ABCB1, also known as MDR1/P-glycoprotein 1 has been impli-
cated in MDR in cancer through efﬂux of xenobiotics. ABCC1/MRP1
has also been implicated inMDR cancer. ABCB1 is composed of six puta-
tive transmembrane domains and a nucleotide binding fold, which is
the site atwhich ATP is processed to provide energy for the efﬂux/trans-
port [54]. ABCB1 has been linked to the efﬂux of many chemotherapeu-
tic drugs such as anthracyclines, and its expression is also known to be
increased in drug-resistant cancer [57]. This highlights ABCB1 as a po-
tential target for drug development, however, strategy to overcome
MDR is challenging due to the widespread expression of ABCB1 in nor-
mal cells [55].
It was previously thought that random genetic mutations could
explain the subset of cancer cells that are drug resistant [58]. However,
recent ﬁndings have suggested that the tumor microenvironment can
facilitate an MDR phenotype through a variety of mechanisms that de-
pend on extracellular matrix signaling to cancer cells and cell adhesion
(reviewed in [58]). Resistance to treatment can be attributed to the in-
duction of efﬂux pump proteins by the microenvironmental factors.
Severalmembers of the family of theABC transporters such as the breast
cancer resistance protein (BCRP) have been shown to be upregulated in
tumor cells under low oxygen conditions. High levels of multidrug
resistance-associated protein-1 (MRP1) and ABCB1 correlate with
drug resistance in leukemia. ABCB1 expression is increased in hypoxic
cells, and this increase is mediated by the hypoxia-inducible factor-1
(HIF-1) [59].
A link between the microenvironment and MDR in leukemia was
recently demonstrated [60], where it was shown that incubation with
bonemarrow-derived stromal cells altered the expression of ABC trans-
porters MDR1, MRP1, MRP2, MRP3 and BCRP in a myeloid leukemia cell
lines and this process was dependent on insulin-like growth factor1.
Our own unpublished data suggest that bone marrow derived condi-
tioned media increases expression of ABC transporter genes ABCC4,
ABCC5, ABCC10, ABCA5 and TAP2 in ALL cell lines. Gene expression of
ABC transporters is controlled through complex networks of signals
that include numerous transcription factors and epigeneticmechanisms
[59,61]. These factors link extracellular signals that include inﬂammato-
ry response (for example IL-6) and growth factors (such as IGF1), to
gene expression of ABC transporter family and thusmaymediatemicro-
environment effects of drug resistance. This highlights a possibility that
themicroenvironment can promote anMDRphenotype. Obtaining a full
awareness and understanding of how the microenvironment may pro-
tect cancer cells is crucial, as there are many ways by which leukemia
may be affected. The following sections will discuss more in-depth the
mechanisms by which the microenvironment exerts its effect.
Table 1
Drugs used to treat leukemia and mechanisms of resistance.
Type of
leukemia
Drug Mechanisms of resistance References
ALL Asparaginase De novo expression of Asn and changes in the expression levels of genes that regulate apoptosis [24]
Clofarabine Downregulation of nucleoside transporters, and upregulation of anti-apoptotic proteins such as Bcl-2 [25]
Daunorubicin Change of MDR gene expression levels [26]
Doxorubicin Upregulation in MDR genes such as MDR1 and MRP1 [27]
Methotrexate Impaired drug uptake, increased drug efﬂux, impaired intracellular polyglutamation, changes in target
enzyme activity and increased intracellular folate pools
[28]
Vincristine Increased microtubule stability, mutations in β-tubulin and increased levels of polymerized tubulin
Increased levels of expression of ABC transporters
[29]
Corticosteroids (dexamethasone or
prednisone)
Low levels of GR protein and reduced activity
Bcl-2 overexpression
[30–34]
AML Cytarabine Reduced drug inﬂux by the hENT1 transporter. Reduced phosphorylation of cytarabine by deoxycytidine
kinase. Increased degradation by 5′-nucleotidase and/or cytidine deaminase. Increased levels of DNA
polymerase alpha. Reduced levels of topoisomerase I/II
[35]
Idarubicin P-glycoprotein-mediated multiple drug resistance [36]
Mitoxantrone Increased Mcl-1 expression and downregulation of topoisomerase IIβ [37]
APL Daunorubicin Change of MDR gene expression levels [26]
Idarubicin P-glycoprotein-mediated multiple drug resistance. [36]
Arsenic trioxide and all-trans retinoic
acid
Increased expression of multidrug resistance-associated protein (MRP1)
Increased intracellular content of glutathione
Mutations in the arsenic-binding domain of PML-RARA
[38,39]
CLL Bendamustine Increased activity of DNA repair enzymes Increased expression of sulfhydryl proteins, e.g., glutathione and
glutathione-related enzymes
[40,41]
Chlorambucil Mutations in p53, increased DNA-PK activity, and increased formation of Rad51 foci [42]
Cyclophosphamide Cyclophosphamide-resistant cell lines exhibit decreased initial levels of DNA interstrand cross-links
following cyclophosphamide treatment (likely due to elevated aldehyde dehydrogenase). These cross-links
are removed more rapidly compared to cyclophosphamide-sensitive cell lines. Glutathione has also been
implicated in resistance (increased DNA repair).
[43–45]
Fludarabine It has been demonstrated that Ku, which is involved in DNA repair, can bind telomerase and that this may be
a mechanism of resistance to ﬂudarabine.
[46]
Alemtuzumab Decreased complement dependent cytotoxicity [47,48]
Rituximab Mesenchymal stromal cells can downregulate CD20, which may be required for Rituximab effect [49]
Corticosteroids (prednisone) See previous entry for ALL [30–34]
CML Cyclophosphamide See previous entry for CLL [43–45]
Cytarabine See previous entry for AML [35]
Tyrosine kinase inhibitors (such as
dasatinib, imatinib, or nilotinib)
Mutations in the BCR-ABL oncogene, increased expression of efﬂux proteins and deregulated apoptotic
pathways
[50]
Plerixafor Increased expression of adhesion molecules and CXCR4 [51]
Mechanisms of resistance may reﬂect ﬁndings from another type of leukemia.
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microvesicles affecting leukemia development and drug resistance
Several studies have demonstrated that bone marrow stromal cells
could mediate chemoresistance and protect leukemic cells from the
cytotoxic effects of therapy. Asparaginase is routinely used in the thera-
py of childhood acute lymphoblastic leukemia (ALL) treatment due to
the fact that ALL cells often depend on exogenous asparagine, as their
own capacity for its production is generally low [62]. Despite this, how-
ever, not all patients respond to this therapy, which indicates further
sources of asparagine production and potential interference with
asparaginase treatment. Mesenchymal stem cells (MSCs), which are
multipotent stromal cells that are thought to reside in hematopoietic
stem cell (HSC) niches, are known to upregulate asparagine synthesis
and protect sensitive leukemia cells from death. It has also been
shown that a subset of leukemic blast cells themselves express lysosom-
al cysteine proteases that degrade the drug asparaginase, leading to re-
sistance [63]. While it is unclear why only some leukemic cells
upregulate the expression of these proteases and others do not, the
most likely explanation lies in the host–tumor interaction [64].
Bonemarrow stromal cells have been implicated in the resistance of
a variety of drugs. Asparaginase is onementioned above, and in addition
to this MSCs have been shown to protect leukemic cells from the cyto-
toxic effects of cytarabine [22]. Another class of drugs commonly used
to treat leukemia are steroids and they regulate several cellular path-
ways to increase apoptosis of white blood cells [32,65]. Effects of micro-
environment on steroid response has been investigated in several
experimental systems [66], including the xenograft models where themechanisms of steroid resistance in leukemic cell lines are different
from those seen in xenografts [67]. Thus, mechanisms of therapeutic
failure need further investigation of molecular details at the basis of
host–tumor interactions.
The tumor microenvironment and primary cancer cells exchange
signals in a two-way process that can lead to evasion of immune re-
sponse, change in TME function, uncontrolled proliferation of cancer
cells, metastasis to form secondary tumors and altered drug response
[68]. The mechanistic details of this process are not entirely known
but involve soluble factors such as secreted signaling molecules and
microvesicles. One of the main categories of soluble factors are cyto-
kines, signaling molecules that are able to induce chemotaxis of target
cells. CXCL12 that is produced by osteoblasts in bone marrow serves
as a ligand for theG-protein coupled receptor CXCR4 andwas suggested
to be one of attractants for hematopoietic stem cells [69,70]. Leukemia
stem cells are also attracted by CXCL12; however, they alter the niche
and secrete another cytokine (SCF, also known as the KIT ligand)
which regulates hematopoiesis and can contribute to the disruption of
normal HSC function. SCF therefore represents an interesting therapeu-
tic target, as its inhibition could potentially maintain normal HSC func-
tion. This has been demonstrated in a mouse model of leukemia where
SCF function was inhibited by neutralizing SCF antibodies [71,72]. An-
other cytokine, proposed to have important function and links immune
response, inﬂammation and microenvironment is interleukin 6 (IL6).
IL6 is cytokine with pro and anti-inﬂammatory effects that controls nu-
merous cellular functions. IL6 expression is increased in ALL patients
bonemarrow, correlates with severity of disease and it facilitates prolif-
eration of multiple myeloma (MM) cells [73,74]. IL6 also mediates
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stroma-mediated drug resistance [75]. In vitro experiments indicated
that blocking IL6 production by stroma restores dexamethasone sensi-
tivity of myeloma cells that have become resistant due to stroma inﬂu-
ence [76]. Inhibition of IL6 actionswithmonoclonal antibody has shown
some improvements in clinical trials and mouse models, although
further development of antibody properties is needed to improve its
therapeutic efﬁcacy [77,78].
In addition to cytokines, several growth factors have been reported
to play a role in leukemia–microenvironment crosstalk. Numerous
growth factors have been hypothesized to contribute to drug resistance
to anticancer kinase inhibitors [79] (Table 2). TGF-β has been docu-
mented to display an inhibitory effect on hematopoiesis. However,
leukemia cells are often resistant to this inhibition despite increased
production of TGF-β by bone marrow stromal cells from leukemia pa-
tients [80–83]. Although TGF-β has been named the molecular Jekyll
and Hyde of cancer, recent evidence indicate that TGF-β neutralizing
antibody in combinationwith cytarabine (that interfereswith DNA syn-
thesis) and CXCR4 antagonist plerixafor increased survival in leukemia
mouse model [84]. Despite the complex picture regarding its actions
these ﬁnding suggest the possibility of using TGF-β as a drug target for
therapy of leukemia.
Other growth factors including basic ﬁbroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF) have also been reported
as important in affecting leukemia development and bone marrow-
mediated resistance to chemotherapy [80]. Increased levels of bFGF
have been observed in CLL patients and correlate with the resistance
to ﬂudarabine [85]. Further deregulation of the FGF pathway has been
reported in patients with multiple myeloma [80]. Anti-apoptotic effects
of VEGF on ALL and CLL cells have been documented and involve alter-
ation of BCL-2 family members and signaling through MAPK pathways.
Another family of growth factors (tumor necrosis factor—TNF family)
has been reported to play a role in microenvironment–leukemia
crosstalk. TNFα is important in hematopoiesis, it has context-
dependent effects on cellular proliferation and it plays important role
in bone marrow function. Deregulation of its signaling can lead to BM
failure and to leukemia stem cell survival [14]. Investigation of the B-
cell receptor (BCR) signaling in CLL indicated that the use of irreversible
BTK inhibitor PCI-32765 (Bruton tyrosine kinase (BTK) that is essential
to BCR function) inhibits CLL cell proliferation and TNF-α-mediated
prosurvival signals [86]. Further support for the role of growth factors
was provided by studies that identiﬁed CC-5013 that is a derivative of
thalidomide as therapy for MM that inhibited bone marrow communi-
cation with myeloma cells that included inhibition of TNF-α, VEGF
and interleukin-6 leading to inhibition of tumor growth, and patient
survival [87]. In addition, the interplay between angiogenic factors
and cells in microenvironment in MM have been reported and de-
scribed in detail [88]. Therefore modulating pathways controlled by
growth factors holds promise for development of new therapies of
leukemia.
It has also been shown that cell supernatants from CLL cells (“condi-
tioned medium”) stimulates the expression of platelet-derived growth
factor receptors (PDGFRs) onmesenchymal stromal cells [89]. Examina-
tion of the conditioned medium showed that platelet-derived growth
factor (PDGF) was present, having been secreted by the leukemia
cells. The authors also showed that high-risk leukemia patients had ele-
vated levels of PDGF. The authors speculated that because PDGF stimu-
lates mesenchymal stromal cell function, this activity would enhance
the ability of themesenchymal cells to protect CLL cells from drug cyto-
toxicity [89]. This highlights how the cells may mutually affect each
other to nurture a drug-resistant phenotype.
The microenvironment can also contribute to leukemic cell survival
through microvesicles such as exosomes. Exosomes are small vesicles
secreted by all cells and found in numerous species from bacteria to
humans suggesting they are conserved through evolution [90,91].
Exosomes are a part of cell–cell communication and can carry variouscargo including proteins, lipids and nucleic acids [92,93]. They are pres-
ent in ﬂuids in the body and have specialized functions such as cell sig-
naling and elimination of cellular waste and are hypothesized to deliver
these signals to speciﬁc target cells [94]. TME and tumor cells interact
via exosomes which can also package immunosuppressive molecules
and micro RNAs (miRs) that promote metastasis and can cause activa-
tion, proliferation or death of target cells [95]. Plasma from patients
with AML and CLL contains higher levels of exosomes than normal
plasma [96], indicating a role for exosomes in cancer development.
Exosomes released by AML cells contain leukemia-speciﬁc coding and
non coding RNA that canmodulate target cell function [97]. The concept
that tumor cells can modify bone marrow microenvironment has been
shown in the case of malignant melanoma suggesting alteration of the
bone marrow progenitor cells towards a cancerous state through
exosome-dependent delivery of oncogenes [68]. Other reports have in-
dicated a similar role of exosomes in hematological malignancies.
Exosomes from B-CLL have been shown to alter AKT signaling and hyp-
oxia response, affecting cyclin D and c-MYC function in bone marrow
stromal cells [98]. It has been shown in CML that the leukemia cells
can produce exosomes which communicate to bone marrow stromal
cells, leading to increased IL8 production. This represents a positive
feedback loop, as IL8 ultimately promotes the survival of leukemia
cells [99]. Bone marrow mesenchymal stromal cells also release
exosomes and they can be different between normal and malignant
bone marrow in solid tumors [94,100]. However, less is known about
the role of bone marrow derived exosomes in this crosstalk in hemato-
logical malignancies. Roccaro and colleagues reported that stromal cells
release exosomes containingmicro RNAs, oncogenic proteins, cytokines
and adhesion factors, that are then transferred to multiple myeloma
cells [101]. Exosomes derived from the normal BM have inhibitory,
whereas exosomes derived from patients with MM had stimulatory ef-
fect on MM tumor growth.
The chemoprotective effect of the bone marrow has been shown on
ALL cells as well [102]. Liu and colleagues simulated the bone marrow
microenvironment in vitro by generating bone marrow stromal con-
ditioned media which was shown to exert a chemoprotective effect.
Tests indicated that this chemoprotective effectwas retained in the pro-
teinase K, RNase and heat resistant fraction of the conditionedmedium.
Furthermore, as conﬁrmed by confocal microscopy, the effect wasmost
likely due to ALL uptake of stromal-derived exosomes enriched inmicro
RNAs. This resulted in aberrant PI3K/AKT and oxidative phosphoryla-
tion in ALL [102]. Our unpublished data indicated that exposure of ALL
cells to conditioned media obtained from the bone marrow cells causes
alteration in ALL cell transcriptome in numerous genes of unknown cel-
lular function (Qattan et al., unpublished observations) highlighting the
need for further studies and potential for therapeutic use of
abovementioned ﬁndings.
1.4. Microenvironment–leukemia cells crosstalk: cell–cell interaction
The importance of cell–cell contact between leukemia cells and cells
of the bone marrow has been investigated previously, with several in-
teresting ﬁndings and approaches. Although accumulation of knowl-
edge regarding mechanisms of cell–cell communication induced drug
resistance has been slow due to technical challenges, it is possible to
model cell–cell contact in vitro through co-culture of leukemia cells
with bone marrow stromal cells. What is important to acknowledge is
that as well as the niche affecting cancer cells, the cancer cells affect
the niche [103].
Obtaining a full understanding of the interactions between the niche
and leukemia is complicated by the fact that there are several different
types of leukemia, and each may interact with the niche differently.
However, despite this, it has been shown that there are some common
signaling pathways to several types of leukemia and lymphoma; for in-
stance, it has been shown that contact with leukemia cells can induce
protein kinase C (PKC)-βII expression in bone marrow stromal cells,
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expression of PKC-βII leads to the activation of NF-κB in tumor stromal
cells, and this pathwaypromotes the survival ofmalignant B cells in vivo
[104]. Indeed, due to the fact that the microenvironment nurtures can-
cer survival, it has been argued that themicroenvironment itself should
be a target for treatment, to bypass the drug resistance that can occur in
cancer cells [104].
Pro-survival effects of themicroenvironmentmay occur through the
inhibition of apoptosis, both spontaneous and drug-induced. It has been
shown that mesenchymal marrow stromal cells are able to protect CLL
cells from spontaneous apoptosis and apoptosis induced by the chemo-
therapeutic drugs dexamethasone and cyclophosphamide [105]. Fur-
thermore, it was shown that direct cell–cell contact was necessary for
this protective effect, at least in this instance, as Kurtova et al. (2009)
[105] separated the leukemia cells from the mesenchymal cells and
found virtually no protective effect.
Several molecules have been shown to be crucial for homing and re-
tention of HSCs and LSCs/leukemic cells to the bone marrow. As previ-
ously stated, CD44 and CD49d (also known as integrin alpha4) were
shown to be crucial in the homing of leukemic cells to the bonemarrow
[7,106]. CD49d binds other molecules, forming active complexes. High
expression levels of CD49d was identiﬁed as an adverse risk factor in
childhood ALL [106], thereby marking it as a potential therapeutic tar-
get. It has been shown that CD49d enhanced chemoresistance to doxo-
rubicin in ALL cells [106,107] and that adhesion of ALL cells to the bone
marrowmicroenvironment is mediated by CD49d. Several mechanisms
for how it may exert its chemoprotective effect have been described.
NF-κB, as previously stated, is involved in pro-survival signaling, and
has been shown to be activated by CD49d signaling. Anti-integrin treat-
ments are currently a widely explored area, with over 260 anti-integrin
drugs currently in clinical evaluation [106]. However, only a fewof these
have been approved for use clinically. Shishido et al.(2014) [106] pro-
vide an in-depth discussion of drugs currently available, citing examples
such as antibodies that target integrin combinations, as well as
discussing potential alternative treatments.
Ultimately, an increased understanding of the mechanisms behind
how cell–cell contact encourages a drug-resistant phenotype will have
important implications for future therapies. The microenvironment
has been shown to affect drug response through both soluble factors
and direct cell–cell contact. If this is more clearly understood, it is possi-
ble that future therapies could be developed that either target the niche
itself to reduce its effect, or target its effector molecules such that they
are no longer able to affect cancerous cells. It has been shown that
some drugs have the ability to reduce cell–cell contact between the
cells of the niche and cancer cells as discussed in the clinical potential
section below.
The microenvironment, however, is not the only way in which tu-
mors may utilize cell–cell contact to survive. As well as contact with
the niche, cell–cell contact is important for tumor survival in a variety
of other ways. Natural killer cells are known to have reduced activity
in CLL, and cell contact with the leukemia cells has been thought to be
a potential mechanism behind this [103]. Again, similar to the above,
patients in early stages of disease had higher counts of natural killer
cells, possibly implying a potential protective effect of natural killer
cells regarding cancer progression [103]. There has beenmuch research
on the role of the inﬂammation and the immune systemand cancer pro-
gression, some of which will be discussed further on in this review.
1.5. Inﬂammation and its role in tumor microenvironment
Inﬂammation is a physiological process that occurs as a response to
infection and injuries, producing inﬂammatory mediators such as cyto-
kines and chemokines [108]. The link between chronic inﬂammation
and cancer was proposed in 1863 by Rudolf Virchow after inﬁltration
of leukocytes in themalignant tissue was observed [109]. In the inﬂam-
matory response macrophages are the most abundant immune cells inthe tumor microenvironment. They are key regulators of the link be-
tween inﬂammation and cancer and have both positive and negative ef-
fects on tumor progression [109–112]. There are different factors that
mediate survival of the macrophages in the tumor which include the
chemokine CCL2 and molecules such as VEGF, PDGF, TGF-β and macro-
phage colony-stimulating factor (M-CSF) [110]. Numerous studies have
revealed that chronic inﬂammation is increased risk factor to certain
types of cancer, and that the inﬂamed tumor microenvironment can
promote tumor progression, modulating the expression of growth fac-
tors, increasing angiogenesis and suppressing immune response [109].
Inﬂammation is considered an important factor of cancer develop-
ment through differentmolecularmechanisms. One transcription factor
crucial for the inﬂammatory response is the NF-κB, which regulates the
expression of a wide range of inﬂammatory molecules, including cyto-
kines and adhesion factors and has also been demonstrated to have a
negative regulatory effect on apoptosis in cancer [113,114]. NF-κB also
contributes to cancer development by stimulating cell proliferation by
positive regulation of growth factor genes, the proto-oncogene c-Myc,
and the cell cycle regulator cyclin D1 [115].
The second group of mediators of inﬂammation are the cytokines,
including interleukins (ILs), TNF-α, growth factors, and colony-
stimulating factors, all of which play a regulatory role in the growth, dif-
ferentiation, and activation of immune cells [116]. Cytokine signaling
contributes to the progression of tumors in two ways: stimulating cell
growth or inhibition of apoptosis of cells affected by inﬂammation.
Moreover, TNF-α and chemokines are believed to be the linking mole-
cules between inﬂammation and cancer, TNF-α is produced mainly by
activated macrophages and plays an important role in inﬂammation
through tissue damage, recovery, remodeling and communication
with microenvironment [117]. TNF-α stimulates inﬂammatory cyto-
kines and increases the expression of growth and adhesion factors.
TNF-α is crucial for NF-κB activation and can induce DNA damage, in-
hibit DNA repair and acts as a growth factor for cancer cells. Further-
more, TNF-α plays a role in promoting angiogenesis and cancer cells
proliferation, and in linking inﬂammation to cancer through regulation
of chemokines [118].
Cytokine family of factors includes chemokines, that are important
for the control of leukocytes migration to the inﬂammatory site. More-
over, chemokines have also been suggested to play a role in facilitation
of cancer growth, invasion and metastasis and in regulating angiogene-
sis. Chemokines may direct tumor cells to their metastatic target tissue
in a similar manner as they control leukocytes [119].
A role of inﬂammation in hematological malignancies is complex
given that cells that mediate immune response are themselves cancer-
ous. Several examples include the effect of chronic inﬂammation in
development of lymphoid cancer including lymphomas associated
with infections in the gastric, ocular and cutaneous systems. Viral infec-
tions also play a role in development of certain types of lymphoma [120,
121]. Increase in the levels of TNF-α and its receptors have been ob-
served in lymphoma and leukemia patients and are prognostic markers
associated with the poor outcome [111,122].
ALL is the most common cancer in children with unknown causes
and increasing incidence [123]. Potential risk factors include environ-
mental exposure to chemicals (such as cigarette smoke), pollution, pes-
ticides and infectious agents. The age and frequency at which infections
occur appear to be important and inverse correlation exists between ex-
posure to infectious agents and development of ALL (as the hygiene hy-
pothesiswould predict) [124,125]. There alsomay be a genetic linkwith
low IL-10 expression at birth in children who later develop ALL. Further
to this, a history of exposure to infectious agents, autoimmune reactions
and chronic inﬂammation have been described as a factor in develop-
ment of CLL [126]. signaling pathways involved were activation of TNF
family members, cytokine IL-4, VEGF and chemokine SDF-1. The micro-
environment was also shown to have inﬂuence [127–129]. Microenvi-
ronment inﬂammation can affect multiple myeloma through similar
mechanisms and increased IL6 production has been associated with
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creased IL6 cytokine production as well as numerous other factors that
affect myeloma and stroma cells (reviewed in [130]). In clinical studies
monoclonal antibodies against IL6 have been shown to demonstrate bi-
ological effect in six myeloma patients [78]. Drugs that inhibit IL6 pro-
duction (thalidomide and its derivative lenalidomide), in combination
with either dexamethasone or proteasome inhibitors have shown sig-
niﬁcant positive activity in myeloma patients [131].
Inﬂammation in general can lead to an increase of inﬂammatoryme-
diators in the blood and inhibition of the effects of anticancer drugs
through actions of cytokines and other molecules. Examples of this in-
clude IL6 and acute phase proteins inactivating anticancer drugs in ex-
perimental mouse systems [131,132]. Also, CYP450 proteins that are
involved in drug metabolism in the liver have shown altered activity
in inﬂammatory states, thus indirectly affecting drug response [133]. Al-
though somemembers of this family are expressed in tissues other than
liver including breast cancer [134] and white blood cells in response to
various stimuli, their function is not well established [135]. Finally, can-
cer therapy can increase inﬂammation leading to adverse effects in my-
eloma and other types of leukemia [130]. In a study of 27 survivors of
childhood ALL and 20 controls, authors have reported deregulation of
immune response and chronic inﬂammation and proposed this to be
the cause of late cardiovascular morbidity [136].
1.6. Immune system and microenvironment
Immune system has been exploited for therapy of numerous dis-
eases and includes use of vaccines andmonoclonal antibodies. In cancer,
few successful examples based on traditional methods include vaccine
against the HPV virus [137] andmonoclonal antibodies for cancer treat-
ment [138]. There are 12 antibodies approved for use in therapy of solid
tumors with the best results obtained with the antibodies against VEGF
and ErbB family. Rituximab and ofatumumab monoclonal antibodies
that target CD20 and alemtuzumab that targets CD52 have been
approved for therapy of CLL and alter apoptotic pathways. Another ap-
proach in treatment of hematological malignancies was to use antibod-
ies in delivery of anticancer agents [138]. Recent approaches have
focussed on investigation of immune surveillance of cancer develop-
ment and potential exploitation of this knowledge to modify immune
system in order to eradicate cancer progression [119,139].
1.7. Evasion of the immunosurveillance in leukemia
The immune surveillance theory proposes that the immune system
recognizes precursor cancer cells and attempts to eradicate them.
Several mechanisms by which the tumor evades immune surveillance
have been described in the literature which could be divided in two
general categories. The ﬁrst refers to the interaction between the
tumor and the immune system mediating changes of the immune
cells that render them incapable to identify tumor cells as foreign to
the host, and the second to the inability of the immune system to detect
the tumor for reasons related either to the ability of the tumor to hide
from the immune systemor its capacity to disguise as benign host tissue
[119,139]. Here selected pathways of tumor evasion of immune surveil-
lance which lead to resistance to anti-cancer therapy are described in
the context of the bone marrow microenvironment and elucidate po-
tential targets to reverse resistance to therapy focusing on hematologi-
cal malignancies.
1.8. Leukemia immune microenvironment
Immune response against leukemic cells is mainly elicited by cyto-
toxic T lymphocytes (CTLs) which recognize leukemia speciﬁc antigens
such as BCR/ABL expressed in CML and ALL and PML/RAR in AML
[reviewed in [14]]. CTLs eliminate efﬁciently virally infected or tumor
cells through binding to an antigen that is presented to them by theinfected or tumor cell in complex with MHC class I molecules. Binding
between the T-cell receptor on CTLs and the MHC class I-antigen com-
plex on the infected or tumor cell takes place through the so-called
‘three-signal activation model’, which results in CTL activation that are
then competent to kill target cells. The process of the speciﬁc interaction
between the CTL and antigens perceived by the immune system as for-
eign to the host requires interaction between the CD8+ molecule on
the surface of the T cell and regions on the MHC class I molecule that
are not bound to the antigen, as well as the presence of other co-
stimulatory signals and release of cytokines by the infected or cancer
cells that fully activate CTL speciﬁc response. T regulatory cells (Treg)
play important role in distinguishing foreign from self-antigen and
therefore in the induction of the CTL killing activity. Leukemic cells dif-
ferentiate and develop in the immunosuppressive Treg-rich bone mar-
row microenvironment and are thereby protected from regular
immune responses [140].
Apart from the inhibitory role of the Treg cells, CTLsmight be unable
to elicit response due to the fact that leukemia associated antigens are
not immunogenic because of diminishedMHC class I expression on leu-
kemic cells which results in deﬁciencies in antigen presentation and
thus malignant cells escaping immunosurveillance [141,142].
Inhibition of CTLs activation can also occur in the presence of
negative regulatory receptors such as the members of the CD28 family
cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell
death-1 (PD-1) which bind to the B7 ligands B7.1 (CD80) and B7.2
(CD86) found on activated antigen presenting cells thereby producing
a co-inhibitory signal decreasing CTLs activity [143]. The T cell immuno-
globulin domain and mucin domain 3 (TIM-3) is another negative reg-
ulatory receptor that was originally found on Th1 cells inducing
tolerance through interaction with its ligand, galectin-9 [144], but
later was detected on other T cells as well, including CD8+ T cells
[145]. TIM-3 is expressed in “exhausted” T cellswhich exhibit functional
unresponsiveness to infections [146] and its blockade using speciﬁc an-
tibodies has shown enhanced anti-tumor T cell responses implying that
TIM-3 inactivation may re-activate T cell responses in cancer patients
[147].
L-tryptophan (L-TRP) is an essential amino acid obtained from food
mainly involved in protein synthesis and is a precursor for several com-
pounds including melatonin, serotonin, kynurenine and nicotinamide
[148]. The heme-containing enzyme indoleamine 2,3-dioxygenase
(IDO) catabolizes tryptophan producing as major metabolite
kynurenine [149],which in turn inhibits T-cell proliferation and induces
T-cell death [150]. It has been shown that IDO is expressed in profes-
sional antigen presenting cells (APCs), dendritic cells particularly, in-
duced by cytokines, including IFN-γ [151]. Transcriptional activation
of IDO gene expression and enzymatic activity following association of
CTLA-4 with CD80/CD86 on the surface of DCs has also been reported
[152,153] indicating that IDO possesses powerful immunomodulatory
activity. Indeed APCs expressing IDO activate Tregs and induce T cell dif-
ferentiation of Tregs thereby intensifying immunosuppression in the
tumor microenvironment [154,155]. IDO expression has been observed
in a substantial number of AML patients implying a signiﬁcant role of
this enzyme in the AML pathophysiology and response to drug treat-
ment [156].2. Clinical potential
There have been several studies onmicroenvironment that show in-
teresting translational potential. Although many studies described pre-
viously in this review focused on the effect of the microenvironment
and bone marrow cells on hematological malignancy survival, it has
been shown that it is possible to target bone marrow stromal cells to
reduce this protective effect. In a study of AML, treatment of bone mar-
row stromal cells with cytarabine was shown to decrease their protec-
tive effect on AML cell death in a dose-dependent manner [157]. This
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order to improve chemotherapy efﬁcacy.
As well as in AML, this concept of targeting the stroma has been
shown for other types of leukemia, including CLL. It has been suggested
that microenvironment offers protection from chemotherapy, often by
aberrant expression of BCL-2 proteins which allows resistance to BCL-
2 inhibitors [158]. However, treatment of co-cultured CLL and stromal
cells with gossypol was shown to overcome the stroma-induced resis-
tance to a BCL-2 inhibitor. More importantly, this study was performed
ex vivo, using CLL cells derived from patients [158],thus providing im-
mediate clinical relevance and potential.
Another interesting target is angiogenesis. Although obviously im-
portant for the metastasis and spread of solid tumors, its role in hema-
tological malignancies was originally less clear [159]. However it has
since been established that angiogenesis does play a role in the develop-
ment of leukemia, suggesting that potential use of anti-angiogenic ther-
apy may improve treatment response in hematological malignancies
[160].Medinger and Passweg (2014) [160] provide a comprehensive re-
view on the role of angiogenesis in hematological malignancies as well
as discussing treatment options. Many anti-angiogenic agents are al-
ready in use in the clinic for other forms of cancer, implying that their
safe use is already well-established. This therefore represents an inter-
esting clinical opportunity as the drugsmay be used directly to treat he-
matologicalmalignancies without the pre-clinical and clinical screening
required for a novel drug.
Interestingly, it has been shown that co-culture ofmultiplemyeloma
cells with BMSCs leads to a signiﬁcant increase in the secretion of both
VEGF and interleukin-6 [161]. This shows that the bonemarrowmicro-
environment itself can drive angiogenesis, and also affects the immune
response. This has interesting therapeutic implications. It has also been
shown that bortezomib can targetmultiplemyeloma and decrease their
adherence to BMSCs, inhibiting their growth and also reducing NF-
κB-dependent induction of interleukin-6 secretion [162].
Another approach that exploits the immune microenvironment for
therapeutic purposes includes targeting the immune system for drug
development. Onemethod to overcome evasion of immunosurveillance
elicited by the tumor and enhance anti-tumor response is to deplete
Tregs. Several approaches have been used to this direction mainly in-
volving the use of anti-CD25 monoclonal antibodies (daclizumab used
in T-cell leukemia patients) [163] to target CD4+ CD25+ FoxP3+
Tregs but the disadvantage of this is that anti-CD25 antibodies can
also target CD25+ T cells [164]. Productive immune response requires
the presence of co-stimulatory and the absence of co-inhibitory signals
such as the CTLA-4 and PD-1. The main role of these immunosuppres-
sive molecules is to protect against self-directed immune responses by
inducing activation of Tregs and hence tolerance, but their over-
expression in cancer cells facilitates evasion of immunosurveillance of
tumors. Therefore targeting co-inhibitory signals with speciﬁc antibod-
ies to block their function would theoretically increase the possibility
that tumors become recognizable by the immune system and offers
the potential for the generation of novel efﬁcient immunotherapies
[165]. The anti-CTLA-4 antibodies ipilimumab and tremelimumab
which block the interaction between CTLA-4 and its ligands CD80 and
CD86 have been tested in a variety of tumors but although they initially
showed promising results in cancer patients [166], serious adverse ef-
fects have restricted their use to limited types of tumors (mainly mela-
noma) and studies continue to investigate their efﬁcacy when they are
used in combination with peptide vaccines [167].
Similarly to CTLA-4 the immunosuppressive function of PD-1 and
the expression of its ligands PD-L1 and PDL-2 on tumor cells [168] has
provided the theoretical basis for the development of immunothera-
peutic approaches against the tolerogenic function of the PD-1 pathway
targeting the PD-1/PD-L1 and PD-1/PD-L2 interaction [169]. Several
antibodies blocking the PD-1/PD-L1 and PD-1/PD-L2 pathways are in
different phases of clinical trials studying their effectiveness in different
types of cancer including hematological malignancies [170]. Theoptimism for the use of these antibodies originates from the fact that
PD-1 is expressed more abundantly than CTLA-4 and therefore it
could offer higher immunogenicity [171]. Some examples of these anti-
bodies are the MDX-1106 (anti-PD1 mAb, Bristol Myers Squibb) [172],
CT-011 (anti-PD1 mAb, CureTech/Teva) [173] and MK-3475 (antiPD-1
mAb, Merck) [174]. Apart from the antibodies blocking PD-1 function
immunotherapeutic approaches targeting the PD-1 ligands have been
developed given that PD-L1 and PD-L2 might exert functions indepen-
dent from their role as PD-1 ligands. Examples of antibodies against
PD-1 ligands are the MPDL3280A/RG7446 (anti-PD-L1, Genentech)
[175], and the MDX-1105 (anti PD-L1mAb Bristol Myers Squibb) [176].
Combination of immune checkpoint CTLA4, PD-1, PD-L1, and PD-L2
blockade with inhibition of the exhausted T cells' biomarker TIM-3
[177] partially restore T cell function and induce antitumor immunity
[178]. The advantage of targeting TIM-3 is that this immunomodulatory
receptor is expressed in speciﬁc types of T cells and mainly in T cells
localized within tumors [179] and hence its inhibition is less likely to
lead to autoimmune responses as compared to CTLA-4 and PD-1 block-
ade [178].
Alternativemethods tomodulate T cell immunity include the inhibi-
tion of the IDO enzymatic activity which has been associated with
induction of immunotolerance, increase of the Tregs number [180]
and poor prognosis [181]. Despite the advantages of the use of IDO in-
hibitors in cancer immunotherapy (reviewed in [182]), side effects
such as the development of autoimmune encephalomyelitis (EAE)
[183] mean that further research is required before they are introduced
in clinical practice.
The above examples have highlighted several potential mechanisms
for research of the microenvironment to be brought into the clinic.
Eventually, the ideal is that a more suitable preclinical model could be
developed thatmore accurately represents what occurs in vivo. One po-
tential model is of tumor-derived xenografts, which seems to be a tech-
nique that faithfully mimics what occurs in patients [184], allowing for
more accurate preclinical data to be gathered. This may ultimately lead
to clinical trials and successful therapy.3. Conclusions
Accumulated evidence has highlighted an essential role for the bone
marrow microenvironment in the development, survival, and persis-
tence of various types of leukemia. The microenvironment affects
various leukemia cell functions and through a variety of different mech-
anisms leads to a chemoresistant phenotype (Fig. 2). However, themul-
tifaceted effects of themicroenvironment on drug resistance complicate
treatment. A variety of approaches are currently being researched to
target the microenvironment and reduce its effect on cancer cells.
Many chemotherapeutic drugs target cycling cells, despite the fact
that LSCs are maintained in a quiescent state (leading to relapse as
they are not eliminated). The use of drugs that target cancer cells re-
gardless of cycling status has been shown to be potentially effective. Ad-
ditional reported strategy was to ﬁrst induce the cell cycle in LSCs and
then use normal chemotherapy that targets cycling cells. Targeting the
chemotactic molecules that drive LSCs towards the niche as well as
targeting the various self-renewal pathways that LSCs use to survive
are also options. This review has discussed several mechanisms behind
microenvironment-mediated drug resistance including the role of in-
ﬂammation and immune surveillance, as well as potential approaches
to mitigate this. Translational research, bringing basic ﬁndings from
bench to bedside, is crucial to improving patient outlook, as is develop-
ment of preclinical models that accurately simulates what occurs in pa-
tients such as tumor-derived xenografts. The immune system has the
potential to eliminate cancer cells and if it can be educated to recognize
them, it would provide a powerful approach to improve survival of can-
cer patients. With a fuller understanding of the microenvironment and
further research into abrogating its chemoprotective effect, it is hoped
Fig. 2. The role of the microenvironment in chemoresistance. Three main mechanisms of chemoprotective effect of the microenvironment on leukemia cells include cell–cell contact,
soluble factors and immune evasion. Key regulators of cell–cell contact are mediators such as integrins. Soluble factors are another way that the microenvironment may exert its effect.
This two-way exchange is mediated through a variety of factors such as cytokines, growth factors, and microvesicles. The immune surveillance theory posits that CTLs (cytotoxic
T lymphocytes) target leukemia and induce cell death. Signaling from the microenvironment may abrogate this. Novel therapies directed towards the limiting the microenvironment–
leukemia crosstalk may improve chemotherapy. Possibilities include targeting stromal cells to reduce adhesion and the resultant protective effect, in addition to interfering with the
soluble factors that are exchanged between stroma and leukemia. The immune system may also be trained to recognize leukemic cells, thus limiting immune evasion and improving
therapy. Figure key: cytokines (yellow square); microvesicles (brown circles) and growth factors (green circles).
Table 2
Strategies to limit microenvironment–leukemia crosstalk.
Biochemical interactions in
the BM niches
Mechanism of BM mediated resistance to chemotherapy Potential therapeutic approaches References
CXCR4–CXCL12 CXCR4 and CXCL12 interaction retains HSCs in BM niche
inaccessible by the drug.
Increased HSCs' afﬁnity to integrins (VLA-4, VLA-5)
increasing adhesion to BM niche
CXCR4 and CXCL12 interaction activates PI3K/Akt and MAPK
pathways inducing HSCs' survival and proliferation.
CXCR4 inhibitors, inhibitors of the CXCR4–CXCL12
interaction
[10,69,70,185]
G-CSF–G-CSFR The plasma levels of G-CSF, which induces HSCs'
mobilization, are normally low to undetectable.
Treatment with G-CSF analogues to induce HSCs'
mobilization
[186]
PTH–PTH1R Parathyroid hormone (PTH)/Parathyroid Hormone Receptor
(PTH1R) [G-protein coupled receptor] ligation induces HSC
expansion and increased survival.
Inhibition of PTH/PTHR1R interaction [187]
VLA-4–VCAM-1, ﬁbronectin Very Late Antigen 4 (VLA-4) plays an important role in the
homing and retention of HSPCs within the bone marrow
microenvironment.
Disruption of the interaction of VLA-4 with its ligands to
induce rapid and reversible mobilization of HSCs into the
peripheral circulation and reduce BM chemoprotective
effect
[7,104–107,188]
c-kit–SCF c-kit binding to SCF activates proliferation, migration, and
differentiation of HSCs.
SCF inhibition leads to restoration of normal HSC activity. [71,72]
Tie2–Ang-1 The receptor tyrosine kinase (Tie2)/Angiopoietin-1 signaling
pathway maintains HSCs in quiescence state and induces
HSCs' adhesion to the BM endosteal niche thereby conferring
chemoresistance to HSCs.
Tie-2-blocking antibodies inhibit growth of AML cells. [189]
ASNS Asparagine synthetase (ASNS) expression in ALL cells is low
rendering them sensitive to asparagine depletion. ASNS
expression levels in bone marrow mesenchymal cells (MSCs)
are high thereby protecting HSCs from asparagine depletion.
L-Asparaginase to deplete L-asparagine [62,64]
Efﬂux pumps, ABC transporters Low oxygen concentration in BM niche induces upregulation
of ABC transporters' gene expression.
Targeting speciﬁc ABC transporters known to be
upregulated in resistant leukemic cells
[55]
TGF-β TGF-β induces HSCs' quiescence in the niche. TGF-β neutralizing antibodies [14,84]
IL-6 MSCs are rich in IL-6 and other cytokines known to induce
HSC expansion and inhibit apoptosis.
Blockage of IL-6 with monoclonal antibodies [75–78,131]
Microvesicles (exosomes) BM-MSCs derived exosomes contain proteins, lipids, mRNA,
and miRNA which they secrete into the niche creating a
chemoresistant environment.
Preventing exosome formation [90–99,190]
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outcome.
4. Future directions
The emerging understanding of the complex crosstalk between the
bone marrow microenvironment and leukemic cells has raised new
challenges. Effective pharmacological targeting of leukemia cells neces-
sitates combinatory targeting of chemotherapeutics targeting leukemic
cells themselves and at the same time their interaction with the bone
marrowmicroenvironment. Prerequisite therefore is to identify the spe-
ciﬁc characteristics of the BMniches andof leukemia cells that facilitates
disease progression and drug resistance. More detailed insight in the
similarities and differences of the cellular and biochemical components
of the BM niches in different types of leukemias and between patients
suffering from the same type of leukemia are important areas to inves-
tigate further.
Moreover recent studies have identiﬁed particular biochemical fac-
tors secreted by cells located in the microenvironment, changing the
physiology of the white blood cells, thereby favoring clonal expansion
and drug resistance. This, as well as signals released by leukemia cells
that alter the architecture of the microenvironment, need to be further
explored.
Another area requiring intensive research effort is the role of the BM
microenvironment in the evasion of immunosurveillance by leukemia
cells. In particular, the detailed understanding of the pathways that leu-
kemia cells use to prevent tumor antigen presentationwill allow the de-
velopment of ex vivo methodologies to “educate” the immune system
to effectively detect neoplastic leukemic cells. Furthermore this ap-
proach could lead to reduced chemoresistance and improved therapies.
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